Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY(2018)
摘要
Objective: To observe the clinical efficacy of lentinan combined with cisplatin and paclitaxel in the treatment of ovarian cancer with ascites. Materials and Methods: Two hundred and twelve cases of patients with epithelial ovarian cancer (EOC) and ascites were retrospectively analyzed. Patients were divided into TP (taxinol + platinol) group and TP + lentinan group according to the chemotherapy regimen. Results: The effective rate (CR + PR) in TP group (98 cases) was 31.6% and disease control rate (CR + PR + SD) was 80.6%. The effective rate in TP + lentinan group (114 cases) was 50.9% and the disease control rate was 88.6%, with statistical difference compared with TP group. The control of ascites in TP + lentinan group was better than TP group. The common adverse reactions of chemotherapy in TP + lentinan group was relative mild with reduced incidence. Conclusion: Lentinan combined with chemotherapy could enhance the efficacy of chemotherapy and control of the ascites.
更多查看译文
关键词
Epithelial ovarian cancer,Lentinan,Taxinol,Platinol,Therapeutic effect
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要